title: Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
abstract: Over the past two decades, progress in the treatment of patients with metastatic squamous non-small-cell lung cancer has been limited. The EGFR is involved in tumor progression and invasion and therefore it has become the target of several studies in lung cancer. Strategies to block this pathway are focused on the development of small molecule (tyrosine kinase inhibitor) and monoclonal antibodies (mAbs). Some mAbs have been studied in patients with advanced non-small-cell lung cancer. For the first time, a fully human immunoglobulin G (IMC-11F8), subclass 1 (IgG1) mAb targeting the EGFR, in combination with standard chemotherapy (cisplatin + gemcitabine), has been shown to increase overall survival in chemo-naïve patients with metastatic confirmed squamous cell histology.
authors: Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy.
authors: Paola Claudia
authors: PC
authors: Sacco
authors: Paolo
authors: P
authors: Maione
authors: Antonio
authors: A
authors: Rossi
authors: Assunta
authors: A
authors: Sgambato
authors: Francesca
authors: F
authors: Casaluce
authors: Giovanni
authors: G
authors: Palazzolo
authors: Cesare
authors: C
authors: Gridelli
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C527969:necitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: NSCLC; anti-EGFR; monoclonal antibody; squamous; target therapy